One year after commissioning a second industrial line that quadrupled the production capacity of its yeasts, microalgae, and bacteria, Silab is now dedicating a new and more spacious space to its biotechnology research laboratory, equipped with the latest technological advances.
“This new facility was necessary to support the growing activity generated by increased customers’ demand for biotechnology products. It is part of a global program of 9 million euros invested over the last three years in biotechnologies, alongside industrial projects,” states Xavier Gaillard, Deputy general manager for strategy at Silab.
Innovative biotechnological raw materials
With this new investments Silab thus invest in new facilities to continue to explore the immense potential of various microorganisms in order to develop innovative biotechnological raw materials for the production of natural active ingredients with high added value.
Brigitte Closs-Gonthier, Deputy general manager for innovation at Silab, adds: “We chose to make biotechnologies a major strategic development axis from very early on, as we believe they represent a powerful innovation lever. Indeed, microorganisms are so diversified that they open up an immense field of possibilities. Biomimetic approaches also make it possible to develop new processes, such as bioguiding. This is an area where much remains to be discovered. It offers tremendous prospects for the development of new innovative active molecules.”
Thanks to the integration of all stages in-house, from the research phase to the industrialization of microorganisms, Silab aims to offer ever more innovative biotechnological solutions, responding to today’s key security issues, traceability, and respect for the environment (sustainability of supplies).
The company’s goal is to continue increasing the share of natural active ingredients of biotechnological origin in its portfolio, which today represents 20% of its catalogue.
